Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataGlobeNewsWire • 08/23/23
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug CandidatesGlobeNewsWire • 11/15/22
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting PatentsGlobeNewsWire • 03/01/22
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/18/22
Organovo Welcomes New Sr. Vice President of Strategy and Business DevelopmentGlobeNewsWire • 02/18/22
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two PatentsGlobeNewsWire • 02/02/22
Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022GlobeNewsWire • 11/30/21
Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of QuorumGlobeNewsWire • 09/17/21
Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers UpsideSeeking Alpha • 05/28/21
Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)GlobeNewsWire • 03/02/21
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 11/07/19